8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Feb 5, 2026·SEC
Ocular Therapeutix, Inc.(OCUL)Earnings, Financials & Key Ratios
OCUL•NASDAQ
Price updated Jun 19, 2026
AboutOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Show more
- Revenue$52M-18.7%
- EBITDA-$266M-58.2%
- Net Income-$266M-37.4%
- EPS (Diluted)-1.42-16.4%
- Gross Margin87.31%-4.2%
- EBITDA Margin-512.7%-94.5%
- Operating Margin-521.04%-93.3%
- Net Margin-513.17%-69.0%
- ROE-54.85%+42.4%
OCUL Key Insights
Ocular Therapeutix, Inc. (OCUL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 24.4%
✗Weaknesses
- ✗Profits declining 11.3% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 18.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OCUL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OCUL Price & Volume
Ocular Therapeutix, Inc. (OCUL) stock price & volume — 10-year historical chart
Loading chart...
OCUL Growth Metrics
Ocular Therapeutix, Inc. (OCUL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years40.33%
5 Years24.39%
3 Years0.21%
TTM-12.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-26.96%
Return on Capital
10 Years-68.94%
5 Years-48.04%
3 Years-49.8%
Last Year-46.01%
OCUL Recent Earnings
Ocular Therapeutix, Inc. (OCUL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.41-28.1%
$0.32
Rev
$11M-15.2%
$13M
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$0.29+12.1%
$0.33
Rev
$13M-17.8%
$16M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.37+5.1%
$0.39
Rev
$15M-9.9%
$16M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.39-11.4%
$0.35
Rev
$13M-7.6%
$15M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.41vs $0.32-28.1% | $11Mvs $13M-15.2% |
| Q1 2026 | Feb 5, 2026 | $0.29vs $0.33+12.1% | $13Mvs $16M-17.8% |
| Q4 2025 | Nov 4, 2025 | $0.37vs $0.39+5.1% | $15Mvs $16M-9.9% |
| Q3 2025 | Aug 5, 2025 | $0.39vs $0.35-11.4% | $13Mvs $15M-7.6% |
Based on last 12 quarters of dataView full earnings history →
OCUL Peer Comparison
Ocular Therapeutix, Inc. (OCUL) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 SGHT | 287.28M | 5.28 | -7.14 | -3.13% | -46.83% | -59.1% | 0.64 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 RXST | 195.81M | 4.73 | -4.98 | -3.89% | -36.58% | -17.01% | 0.04 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 |
Compare OCUL vs Peers
Ocular Therapeutix, Inc. (OCUL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCUL Income Statement
Ocular Therapeutix, Inc. (OCUL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.92M | 1.99M | 4.23M | 17.4M | 43.52M | 51.49M | 58.44M | 63.72M | 51.82M | 52.04M |
Revenue Growth % | 1.91% | 3.48% | 112.41% | 311.71% | 150.08% | 18.32% | 13.49% | 9.03% | -18.67% | -12.76% |
Cost of Goods Sold | 457K | 465K | 2.33M | 2.08M | 4.41M | 4.54M | 5.28M | 5.63M | 6.57M | 6.64M |
COGS % of Revenue | 23.77% | 23.37% | 55% | 11.97% | 10.12% | 8.82% | 9.04% | 8.83% | 12.69% | - |
Gross Profit | 1.47M▲ 0% | 1.52M▲ 4.0% | 1.9M▲ 24.7% | 15.32M▲ 705.5% | 39.12M▲ 155.3% | 46.95M▲ 20.0% | 53.16M▲ 13.2% | 58.1M▲ 9.3% | 45.25M▼ 22.1% | 45.4M▲ 0% |
Gross Margin % | 76.23% | 76.63% | 45% | 88.03% | 89.88% | 91.18% | 90.96% | 91.17% | 87.31% | 87.24% |
Gross Profit Growth % | 1.52% | 4.02% | 24.72% | 705.47% | 155.33% | 20.04% | 13.22% | 9.28% | -22.11% | - |
Operating Expenses | 63.39M | 60.64M | 87.7M | 78.17M | 117.15M | 125.61M | 135.54M | 229.88M | 315.39M | 344.84M |
OpEx % of Revenue | 3296.36% | 3047.39% | 2074.85% | 449.16% | 269.18% | 243.93% | 231.93% | 360.75% | 608.6% | - |
Selling, General & Admin | 32.51M | 23.73M | 46.61M | 49.47M | 67.07M | 72.15M | 74.49M | 102.24M | 118.3M | 124.38M |
SG&A % of Revenue | 1690.54% | 1192.36% | 1102.74% | 284.28% | 154.11% | 140.11% | 127.46% | 160.45% | 228.27% | - |
Research & Development | 30.88M | 36.91M | 41.09M | 28.69M | 50.08M | 53.46M | 61.05M | 127.64M | 197.1M | 220.45M |
R&D % of Revenue | 1605.82% | 1855.03% | 972.11% | 164.88% | 115.08% | 103.82% | 104.47% | 200.3% | 380.33% | - |
Other Operating Expenses | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -61.92M▲ 0% | -59.12M▲ 4.5% | -85.8M▼ 45.1% | -62.85M▲ 26.8% | -78.04M▼ 24.2% | -78.65M▼ 0.8% | -82.38M▼ 4.7% | -171.78M▼ 108.5% | -270.02M▼ 57.2% | -299.44M▲ 0% |
Operating Margin % | -3220.12% | -2970.75% | -2029.86% | -361.13% | -179.3% | -152.74% | -140.96% | -269.57% | -521.04% | -575.42% |
Operating Income Growth % | -42.92% | 4.53% | -45.14% | 26.75% | -24.17% | -0.79% | -4.74% | -108.52% | -57.19% | - |
EBITDA | -60.3M | -56.83M | -83.27M | -60.07M | -75.62M | -76.55M | -79.4M | -168M | -265.69M | -294.81M |
EBITDA Margin % | -3135.62% | -2855.88% | -1970% | -345.19% | -173.74% | -148.65% | -135.86% | -263.63% | -512.7% | -566.53% |
EBITDA Growth % | -42.06% | 5.75% | -46.52% | 27.86% | -25.87% | -1.23% | -3.73% | -111.58% | -58.16% | -47.23% |
D&A (Non-Cash Add-back) | 1.63M | 2.29M | 2.53M | 2.77M | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M | 4.63M |
EBIT | -61.49M | -58.24M | -80.27M | -148.87M | 118K | -64.02M | -69.4M | -179.93M | -254.1M | -286.38M |
Net Interest Income | -1.47M | -860K | -4.87M | -6.6M | -6.64M | -6.22M | -7.36M | 6.71M | 6.52M | 8.95M |
Interest Income | 424K | 879K | 1.23M | 168K | 33K | 798K | 3.98M | 20.28M | 18.36M | 20.58M |
Interest Expense | 1.89M | 1.74M | 6.1M | 6.77M | 6.67M | 7.02M | 11.34M | 13.58M | 11.84M | 11.63M |
Other Income/Expense | -1.46M | -860K | -570K | -92.79M | 71.48M | 7.62M | 1.65M | -21.73M | 4.08M | 8.94M |
Pretax Income | -63.39M▲ 0% | -59.98M▲ 5.4% | -86.37M▼ 44.0% | -155.64M▼ 80.2% | -6.55M▲ 95.8% | -71.04M▼ 984.1% | -80.74M▼ 13.7% | -193.51M▼ 139.7% | -265.94M▼ 37.4% | -290.5M▲ 0% |
Pretax Margin % | -3296.2% | -3013.97% | -2043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -303.67% | -513.17% | -558.24% |
Income Tax | 272K | -2.29M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.43% | 3.81% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -63.39M▲ 0% | -57.69M▲ 9.0% | -86.37M▼ 49.7% | -155.64M▼ 80.2% | -6.55M▲ 95.8% | -71.04M▼ 984.1% | -80.74M▼ 13.7% | -193.51M▼ 139.7% | -265.94M▼ 37.4% | -290.5M▲ 0% |
Net Margin % | -3296.2% | -2899.1% | -2043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -303.67% | -513.17% | -558.24% |
Net Income Growth % | -41.79% | 8.98% | -49.71% | -80.19% | 95.79% | -984.05% | -13.65% | -139.68% | -37.43% | -50.74% |
Net Income (Continuing) | -63.39M | -59.98M | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M | -193.51M | -265.94M | -290.5M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.20▲ 0% | -1.57▲ 28.6% | -1.91▼ 21.7% | -2.56▼ 34.0% | -0.98▲ 61.7% | -0.97▲ 1.0% | -1.02▼ 5.2% | -1.22▼ 19.6% | -1.42▼ 16.4% | -1.30▲ 0% |
EPS Growth % | -22.22% | 28.64% | -21.66% | -34.03% | 61.72% | 1.02% | -5.15% | -19.61% | -16.39% | -26.96% |
EPS (Basic) | -2.20 | -1.57 | -1.91 | -2.56 | -1.05 | -1.04 | -1.09 | -1.22 | -1.42 | - |
Diluted Shares Outstanding | 28.82M | 38.12M | 45.27M | 60.75M | 82.16M | 82.64M | 85.6M | 158.26M | 187.24M | 224.1M |
Basic Shares Outstanding | 28.82M | 38.12M | 45.27M | 60.75M | 76.39M | 76.88M | 79.83M | 158.26M | 187.24M | 224.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
OCUL Balance Sheet
Ocular Therapeutix, Inc. (OCUL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 43.34M | 56.19M | 60.17M | 246.16M | 191.3M | 129.63M | 232.24M | 440.99M | 782.13M | 706M |
Cash & Short-Term Investments | 41.54M | 54.06M | 54.44M | 228.06M | 164.16M | 102.3M | 195.81M | 392.1M | 737.06M | 666.7M |
Cash Only | 41.54M | 54.06M | 54.44M | 228.06M | 164.16M | 102.3M | 195.81M | 392.1M | 737.06M | 666.7M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 226K | 201K | 2.55M | 12.25M | 21.14M | 21.32M | 26.18M | 32.39M | 30.65M | 24.35M |
Days Sales Outstanding | 42.9 | 36.87 | 220.02 | 256.97 | 177.25 | 151.16 | 163.5 | 185.52 | 215.87 | 203.72 |
Inventory | 122K | 217K | 954K | 1.2M | 1.25M | 1.97M | 2.31M | 3.04M | 3.56M | 3.74M |
Days Inventory Outstanding | 97.44 | 170.33 | 149.77 | 210.45 | 103.55 | 158.7 | 159.31 | 197.23 | 197.88 | 190 |
Other Current Assets | 108K | 1.71M | 0 | 0 | 0 | 4.03M | 7.94M | 13.46M | 10.86M | 11.21M |
Total Non-Current Assets | 12.09M | 16.85M | 18.57M | 15.7M | 13.59M | 19.66M | 19.82M | 16.95M | 25.93M | 26.53M |
Property, Plant & Equipment | 10.48M | 10.24M | 16.81M | 13.94M | 11.82M | 17.9M | 18.21M | 15.33M | 24.31M | 24.92M |
Fixed Asset Turnover | 0.18x | 0.19x | 0.25x | 1.25x | 3.68x | 2.88x | 3.21x | 4.16x | 2.13x | 2.37x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.61M | 6.61M | 0 | 0 | 0 | 0 | 0 | 0 | 1.61M | 4.84M |
Other Non-Current Assets | 0 | 0 | 1.76M | 1.76M | 1.76M | 1.76M | 1.61M | 1.61M | 0 | 0 |
Total Assets | 55.43M▲ 0% | 73.04M▲ 31.8% | 78.74M▲ 7.8% | 261.86M▲ 232.6% | 204.89M▼ 21.8% | 149.29M▼ 27.1% | 252.06M▲ 68.8% | 457.94M▲ 81.7% | 808.06M▲ 76.5% | 732.53M▲ 0% |
Asset Turnover | 0.03x | 0.03x | 0.05x | 0.07x | 0.21x | 0.34x | 0.23x | 0.14x | 0.06x | 0.09x |
Asset Growth % | -26.03% | 31.77% | 7.8% | 232.57% | -21.76% | -27.14% | 68.84% | 81.68% | 76.46% | 127.99% |
Total Current Liabilities | 13.43M | 9.16M | 12.03M | 26.66M | 26.34M | 31.39M | 34.9M | 41.35M | 50.81M | 47.68M |
Accounts Payable | 3.57M | 2.96M | 3.27M | 2.71M | 4.59M | 5.12M | 4.39M | 4.18M | 4.15M | 8.03M |
Days Payables Outstanding | 2.85K | 2.33K | 513.04 | 474.69 | 380.41 | 411.87 | 303.35 | 270.93 | 230.64 | 334.29 |
Short-Term Debt | 5.54M | 0 | 0 | 8.29M | 0 | 0 | 0 | 0 | 2.82M | 3.17M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 576K | 255K | 128K | 0 | 14M |
Other Current Liabilities | 1.37M | 2.64M | 0 | 0 | 0 | 0 | 0 | 0 | 25.86M | 22.49M |
Current Ratio | 3.23x | 6.14x | 5.00x | 9.23x | 7.26x | 4.13x | 6.66x | 10.66x | 15.39x | 14.81x |
Quick Ratio | 3.22x | 6.11x | 4.92x | 9.19x | 7.22x | 4.07x | 6.59x | 10.59x | 15.32x | 14.73x |
Cash Conversion Cycle | -2.71K | -2.12K | -143.25 | -7.28 | -99.61 | -102.01 | 19.46 | 111.82 | 183.12 | 59.43 |
Total Non-Current Liabilities | 15.86M | 28.01M | 70.34M | 159.1M | 90.55M | 82.52M | 126.03M | 101.24M | 102.94M | 103.27M |
Long-Term Debt | 12.47M | 24.79M | 49.31M | 41.24M | 51.44M | 54.01M | 74.92M | 68.5M | 74.15M | 76.29M |
Capital Lease Obligations | 0 | 0 | 8.9M | 7.55M | 5.92M | 8.68M | 6.88M | 5.34M | 2.81M | 15.08M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.39M | 3.22M | 12.12M | 98.31M | 20.19M | 6.44M | 30.09M | 13.39M | 11.97M | 12.98M |
Total Liabilities | 29.28M | 37.17M | 82.37M | 185.77M | 116.89M | 113.91M | 160.93M | 142.59M | 153.75M | 150.96M |
Total Debt | 18.02M | 24.79M | 59.34M | 58.44M | 58.98M | 64.28M | 83.39M | 75.78M | 79.78M | 79.46M |
Net Debt | -23.52M | -29.27M | 4.91M | -169.62M | -105.18M | -38.02M | -112.42M | -316.32M | -657.28M | -587.24M |
Debt / Equity | 0.69x | 0.69x | - | 0.77x | 0.67x | 1.82x | 0.92x | 0.24x | 0.12x | 0.14x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.27x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.99x |
Interest Coverage | -32.50x | -33.49x | -13.16x | -22.00x | 0.02x | -9.12x | -6.12x | -13.25x | -21.47x | -24.63x |
Total Equity | 26.15M▲ 0% | 35.88M▲ 37.2% | -3.63M▼ 110.1% | 76.09M▲ 2196.3% | 88M▲ 15.6% | 35.38M▼ 59.8% | 91.13M▲ 157.6% | 315.34M▲ 246.0% | 654.31M▲ 107.5% | 581.57M▲ 0% |
Equity Growth % | -49.73% | 37.2% | -110.12% | 2196.28% | 15.64% | -59.8% | 157.59% | 246.03% | 107.49% | 180.54% |
Book Value per Share | 0.91 | 0.94 | -0.08 | 1.25 | 1.07 | 0.43 | 1.06 | 1.99 | 3.49 | 2.60 |
Total Shareholders' Equity | 26.15M | 35.88M | -3.63M | 76.09M | 88M | 35.38M | 91.13M | 315.34M | 654.31M | 581.57M |
Common Stock | 3K | 4K | 5K | 8K | 8K | 8K | 12K | 16K | 22K | 22K |
Retained Earnings | -237.26M | -297.24M | -383.62M | -539.25M | -545.8M | -616.84M | -697.58M | -891.08M | -1.16B | -1.25B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCUL Cash Flow Statement
Ocular Therapeutix, Inc. (OCUL) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -50.47M | -49.23M | -77.58M | -53.55M | -65.55M | -59.6M | -70.23M | -134.68M | -204.88M | -226.21M |
Operating CF Margin % | -2624.7% | -2473.72% | -1835.3% | -307.73% | -150.61% | -115.75% | -120.18% | -211.35% | -395.35% | - |
Operating CF Growth % | -48.45% | 2.47% | -57.59% | 30.97% | -22.4% | 9.07% | -17.84% | -91.75% | -52.13% | -246.78% |
Net Income | -63.39M | -59.98M | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M | -193.51M | -265.94M | -290.5M |
Depreciation & Amortization | 1.63M | 2.29M | 2.53M | 2.77M | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M | 4.63M |
Stock-Based Compensation | 7.32M | 7.48M | 8.76M | 7.53M | 14.98M | 16.96M | 17.82M | 33.11M | 43.18M | 36.62M |
Deferred Taxes | 9K | 0 | -4.3M | 86.19M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 408K | 397K | 3.68M | 4.41M | -73.49M | -8.99M | -2.9M | 32.16M | 5.84M | 19.91M |
Working Capital Changes | 3.55M | 585K | -1.88M | 1.18M | -2.9M | 1.35M | -7.41M | -10.23M | 7.71M | 3.14M |
Change in Receivables | 24K | 25K | -2.35M | -9.7M | -8.88M | -190K | -4.85M | -6.21M | 1.74M | 874K |
Change in Inventory | -9K | -95K | -737K | -247K | -49K | -724K | -331K | -735K | -524K | -468K |
Change in Payables | 932K | -796K | 124K | -452K | 1.8M | -621K | 583K | -318K | -887K | 2.83M |
Cash from Investing | 27.07M | -1.89M | -2.24M | -841K | -1.19M | -3.71M | -6.09M | -1.29M | -11.88M | -14.61M |
Capital Expenditures | -8.25M | -1.89M | -2.24M | -841K | -1.19M | -3.71M | -6.09M | -1.29M | -12.01M | -14.74M |
CapEx % of Revenue | 429.12% | 94.92% | 52.95% | 4.83% | 2.74% | 7.21% | 10.42% | 2.02% | 23.18% | 28.32% |
Acquisitions | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 114K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 130K | 130K |
Cash from Financing | 32.01M | 68.64M | 75.34M | 228.01M | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M | 557.83M |
Debt Issued (Net) | 2.4M | 6.38M | 37.27M | 0 | -445K | 0 | 56.35M | 316.35M | 0 | 0 |
Equity Issued (Net) | 29.24M | 61.57M | 37.54M | 224.68M | 985K | 940K | 118.11M | 316.35M | 561.72M | 557.83M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 370K | 694K | 529K | 3.33M | 2.31M | 514K | -4.63M | -300.6M | 0 | 0 |
Net Change in Cash | 8.6M▲ 0% | 17.52M▲ 103.7% | -4.47M▼ 125.5% | 173.62M▲ 3979.8% | -63.89M▼ 136.8% | -61.86M▲ 3.2% | 93.51M▲ 251.1% | 196.15M▲ 109.8% | 344.96M▲ 75.9% | 317.02M▲ 0% |
Free Cash Flow | -58.73M▲ 0% | -51.12M▲ 13.0% | -79.82M▼ 56.1% | -54.4M▲ 31.8% | -66.74M▼ 22.7% | -63.32M▲ 5.1% | -76.32M▼ 20.5% | -135.97M▼ 78.1% | -216.89M▼ 59.5% | -240.94M▲ 0% |
FCF Margin % | -3053.82% | -2568.64% | -1888.24% | -312.56% | -153.36% | -122.96% | -130.59% | -213.37% | -418.53% | -463.02% |
FCF Growth % | -63.49% | 12.96% | -56.15% | 31.85% | -22.7% | 5.13% | -20.54% | -78.15% | -59.52% | -62.33% |
FCF per Share | -2.04 | -1.34 | -1.76 | -0.90 | -0.81 | -0.77 | -0.89 | -0.86 | -1.16 | -1.08 |
FCF Conversion (FCF/Net Income) | 0.80x | 0.85x | 0.90x | 0.34x | 10.00x | 0.84x | 0.87x | 0.70x | 0.77x | 0.83x |
Interest Paid | 0 | 0 | 0 | 0 | 1.93M | 2.15M | 5.46M | 0 | 0 | 2.24M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCUL Key Ratios
Ocular Therapeutix, Inc. (OCUL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -162.21% | -186.04% | -535.72% | -429.55% | -7.99% | -115.16% | -127.64% | -95.21% | -54.85% | -64.55% |
Return on Invested Capital (ROIC) | -248.75% | -961.16% | -1633.91% | - | - | - | - | - | - | 3070.22% |
Gross Margin | 76.23% | 76.63% | 45% | 88.03% | 89.88% | 91.18% | 90.96% | 91.17% | 87.31% | 87.24% |
Net Margin | -3296.2% | -2899.1% | -2043.34% | -894.31% | -15.06% | -137.95% | -138.14% | -303.67% | -513.17% | -558.24% |
Debt / Equity | 0.69x | 0.69x | - | 0.77x | 0.67x | 1.82x | 0.92x | 0.24x | 0.12x | 0.14x |
Interest Coverage | -32.50x | -33.49x | -13.16x | -22.00x | 0.02x | -9.12x | -6.12x | -13.25x | -21.47x | -24.63x |
FCF Conversion | 0.80x | 0.85x | 0.90x | 0.34x | 10.00x | 0.84x | 0.87x | 0.70x | 0.77x | 0.83x |
Revenue Growth | 1.91% | 3.48% | 112.41% | 311.71% | 150.08% | 18.32% | 13.49% | 9.03% | -18.67% | -12.76% |
Related:OCUL Dividend History·OCUL Revenue History·OCUL Price History·OCUL P/E History·OCUL Financial Ratios·OCUL Institutional Holders
OCUL SEC Filings & Documents
Ocular Therapeutix, Inc. (OCUL) SEC filings — annual & quarterly reports (10-K, 10-Q)
OCUL Frequently Asked Questions
Ocular Therapeutix, Inc. (OCUL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ocular Therapeutix, Inc. (OCUL) reported $52.0M in revenue for fiscal year 2025. This represents a 520280% increase from $0.0M in 2012.
Ocular Therapeutix, Inc. (OCUL) saw revenue decline by 18.7% over the past year.
Ocular Therapeutix, Inc. (OCUL) reported a net loss of $290.5M for fiscal year 2025.
Dividend & Returns
Ocular Therapeutix, Inc. (OCUL) has a return on equity (ROE) of -54.9%. Negative ROE indicates the company is unprofitable.
Ocular Therapeutix, Inc. (OCUL) had negative free cash flow of $240.9M in fiscal year 2025, likely due to heavy capital investments.